Background Preventing mother to child transmission of chronic hepatitis B infection in the
setting of a high maternal viral load is challenging. The idea has emerged from antepartum …

The goal of antiviral therapy is to improve the quality of life and survival of patients with
chronic hepatitis B (CHB) by halting the progression to cirrhosis, end‐stage liver disease or …

The Chinese Society of Hepatology, Chinese Medical Association (CMA) and the Society of
Infectious Diseases, CMA organized relevant native experts to establish this Guideline of …

A major hurdle in the long‐term treatment of chronic hepatitis B (CHB) patients is to maintain
viral suppression in the absence of drug resistance. To date, no evidence of resistance to …

Background Findings from uncontrolled studies suggest that addition of pegylated interferon
in patients with HBe antigen (HBeAg)-negative chronic hepatitis B receiving nucleos (t) ide …

Abstract Scope Hepatitis B virus (HBV) infection reactivation is associated with high
morbidity and mortality in patients with haematologic malignancy and/or haematopoietic …

Hepatitis virus infection is a leading cause of chronic liver disease, including cirrhosis and
hepatocellular carcinoma (HCC). Although anti-viral therapies against hepatitis B virus …

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and the
second most common cause of cancer deaths worldwide. The top three causes of HCC are …

Background Long-term antiviral therapy has resulted in viral suppression and biochemical
response in chronic hepatitis B, although the risk of hepatocellular carcinoma has not been …

The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease
progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is …